Role of ICAM-1 and E-selectin gene polymorphisms in pathogenesis of PAOD in Egyptian patients
Olfat Shaker1, Amr Zahra2, Ahmed Sayed3, Ayman Refaat4, Zakaria El-Khaiat5, Gehan Hegazy5, Khaled El-Hindawi3, Mohamed Ay-El Deen3
1Department of Medical Biochemistry, 3Vascular Surgery, Faculty of Medicine, Cairo University, Cairo, Egypt; 2Department of Medical Biochemistry, Faculty of Medicine, Fayoum University, Al Fayyum, Egypt; 4Vasular Surgery, Faculty of Medicine, Beni Suef University, Beni-Suef, Egypt; 5Medical Biochemistry Department, National Research Center, Cairo, Egypt
Background: Intercellular adhesion molecule-1 (ICAM-1) and E-selectin have been shown to predict cardiovascular disease (CVD) such as myocardial infarction, stroke, and peripheral arterial occlusive disease (PAOD).
Methods: Two mutations, S128R in E-selectin and K469E in ICAM-1, were investigated in 156 patients with PAOD and 100 control subjects using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) analysis in an Egyptian population.
Results: The distribution of E-selectin genotypes in patients affected by PAOD was 84.6% for the AA genotype and 15.4% for the AC genotype. In the control arm the distribution was 97% for the AA genotype and 3% for the AC genotype. There was a statistically significance difference in the distribution of the AC genotype in PAOD patients when compared with the control subjects. Additionally, the distribution of ICAM-1 genotypes in patients affected by PAOD was 30.8% with the EE, 48% with the EK, and 21.2% with the KK genotypes. The distribution of ICAM-1 genotypes in control subjects was 13% EE, 33% EK and 54% KK. The EE genotype was significantly more common in PAOD patients than in the controls.
Conclusion: S128R and K469E polymorphisms were associated with increased risk in PAOD. Early detection of these polymorphic genes helps in early prophylaxis against PAOD.
Keywords: polymorphism, PAOD, E-selectin, ICAM-1, RFLP, genotyping
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF]